The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence
The DOI matches its Crossref record, with a small difference in title or year; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Long-acting injectable antipsychotics (LAIs) are among the most effective treatments in psychiatry, yet they remain underutilized in clinical practice. Although LAIs are typically used to maintain treatment adherence in patients with chronic schizophrenia, recent research has suggested that they may also provide an effective treatment strategy for patients with early-phase or first-episode disease. In October 2015, a group of 8 experts on the management of schizophrenia and LAIs met to evaluate the evidence surrounding the efficacy, safety, and cost-effectiveness of LAIs and to develop practical recommendations regarding the clinical use, education, and unmet needs related to LAIs. Participants were also asked to rate the importance of several patient characteristics when choosing an LAI versus an oral antipsychotic, from the perspectives of 4 different stakeholder groups: patients, health care professionals, families, and payers. The evidence review demonstrated that LAIs are superior to placebo for acute and maintenance treatment of schizophrenia and, in general, appear to be similar to one another in terms of schizophrenia relapse prevention. Study design impacts the demonstrated efficacy of LAIs versus oral antipsychotics, but recent database and randomized controlled studies favor the use of LAIs in early-phase schizophrenia patients. LAIs vary considerably in their propensity to cause certain adverse effects, including weight gain, metabolic effects, extrapyramidal symptoms, and prolactin elevation, and these differences can be used to help guide LAI selection. Some studies, but not all, have demonstrated significant reductions in health care utilization or overall costs with LAIs. The expert panel identified several barriers to LAI use in current practice, including clinician lack of knowledge, negative attitudes about LAIs, and resource and cost issues. The participants also identified a number of additional factors that should be considered when weighing the use of LAI therapy, including medication adherence, relapse risk and severity, cognitive impairment, ease of use, substance misuse, access and cost, stigma, social support, patient autonomy, control over medication dosing, fear of needles, and the potential for patient harm due to relapses and associated loss of functioning. This evidence review, discussion, and summary recommendations may help clinicians, patients, families, payers, and other stakeholders to better characterize the role of LAIs in the treatment of schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to the benefits of reduced treatment gaps with LAI versus oral antipsychotics, studies, particularly those in real-world samples, have demonstrated reduced psychopathology, relapses, hospitalizations, and mortality risk with LAI formulations [98–104].”
From Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview (2021) · cites this paper as [100]
In the citing paper
“Longacting injectable antipsychotics can enhance adherence, 10 but surveys of physician attitudes about LAIs show that they consider LAIs primarily for patients who have already had repeated hospitalizations and relapses.11”
From Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial (2020) · cites this paper as [10]
In the citing paper
“Currently, a number of studies have proven the effectiveness, safety and tolerability of LAIs [25]”
From The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review (2020) · cites this paper as [25]
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
Items 201–300 of 372
Sánchez, P., Álamo, C., Almendros, M., Schlueter, M., Tasoulas, A., & Martínez, J. (2023) · Annals of General Psychiatry · doi:10.1186/s12991-023-00464-z · Cited by 12
Cirnigliaro, G., Battini, V., Castiglioni, M., Renne, M., Mosini, G., Cheli, S., Carnovale, C., & Dell’Osso, B. M. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2325655 · Cited by 8
Rodolico, A., Aprile, S. F., Cutrufelli, P., Privitera, G., Castellano, S., Concerto, C., Furnari, R., Guerrera, C. S., Mineo, L., Platania, G. A., et al. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01391-x · Cited by 10
Citrome, L., Correll, C. U., Cutler, A. J., Dunbar, M., Hoberg, A. R., Hopkinson, C., Mattingly, G. W., McGrory, J. A., Rege, B., Weiden, P. J., et al. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s499367 · Cited by 9
Self-citationMiller, B. J., Claxton, A., Du, Y., Weiden, P. J., & Potkin, S. G. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.01.038 · Cited by 7
Bardwell, G., Jaffe, K., Korthuis, P. T., & Richardson, L. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000772 · Cited by 9
Chan, H., Huang, C.-Y., & Yen, Y. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03513-7 · Cited by 7
Dunnett, D. A., Oloyede, E., Oduniyi, O., Arroyo, B., Dzahini, O., Taylor, D. M., Shergill, S. S., & Whiskey, E. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211050561 · Cited by 7
Tang, C., Shen, S., Huang, M., Qiu, H., Watanabe, S., Goh, C. H., & Liu, Y. (2021) · European Psychiatry · doi:10.1192/j.eurpsy.2021.2258 · Cited by 8
Martínez‐Giner, G., Llano, E. G., Romero-Rubio, D., Abad‐Pérez, M. J., & Sánchez‐Martínez, V. (2022) · International Journal of Mental Health Nursing · doi:10.1111/inm.12973 · Cited by 8
Preskorn, S. (2017) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000236 · Cited by 7
Bardi, F., Moccia, L., Kotzalidis, G. D., Boggio, G., Brugnami, A., Sfratta, G., Janiri, D., Sani, G., & Simonetti, A. (2025) · Healthcare · doi:10.3390/healthcare13141709 · Cited by 9
Zhang, L., Wu, T., Li, J., Du, C., Chi, R., Jiang, K., Qiu, H., Hsu, Y., Dong, W., Wang, H., et al. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251360400 · Cited by 6
Santorelli, M., Miuli, A., Pettorruso, M., Carlo, F. D., Berardis, D. D., Sensi, S. L., Martinotti, G., Clerici, M., & Giannantonio, M. D. (2024) · Current Neuropharmacology · doi:10.2174/1570159x23666241023115252 · Cited by 8
Trovini, G., Lombardozzi, G., Kotzalidis, G. D., Lionetto, L., Russo, F., Sabatino, A. D., Serra, E., Castorina, S., Civita, G., Frezza, S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031394 · Cited by 10
Perlstein, I., Wagner, A. M., Elgart, A., Zandvliet, A. S., Hellmann, F., Lin, Y., van Maanen, E., Plock, N., Fauchet, F., & Singh, R. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00723-z · Cited by 9
Samalin, L., Boudieu, L., & Llorca, P. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2313550 · Cited by 6
Hsu, H.-F., Kao, C., Lu, T., Ying, J. C., & Lee, S.-Y. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060823 · Cited by 7
Díaz-Fernández, S., Frías-Ortiz, D. F., & Miranda, J. J. F. (2019) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2019.04.004 · Cited by 8
Delayed Onset Postinjection Delirium/Sedation Syndrome Associated With Olanzapine Pamoate
Garg, S., Gupta, D., Rakesh, K., & Tikka, S. K. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001091 · Cited by 6
Long-Acting Injectable versus Oral Antipsychotics for Restoration of Competency to Stand Trial.
Ghossoub, E., Minchin, S. A., Hayreh, D., & Newman, W. J. (2019) · PubMed · doi:10.29158/jaapl.003866-19 · Cited by 7
Velligan, D. I., Sajatovic, M., Sierra, C., Mintz, J., Merker, J. M., Cassidy, K. A., & Runnels, P. S. (2021) · Psychiatric Services · doi:10.1176/appi.ps.201900545 · Cited by 8
Sathienluckana, T., Tiangpattanawong, P., Chaiyasukthananoan, K., Jittayanan, P., Sawetwangsing, H., & Puchsaka, P. (2021) · Schizophrenia Research and Treatment · doi:10.1155/2021/8403986 · Cited by 8
Physician Characteristics Associated With Prescription of Long-Acting Injectable Antipsychotics
Stip, É. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16lr11401 · Cited by 5
Martins, P. S., Caldas, F., Oliveira, C., Mota, J. C., & Gonçalves, M. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114581 · Cited by 8
Matsuzaka, Y., Noguchi, M., Kanamura, S., Maeda, K., Hisano, T., Tanaka, D., Ando, Y., Yamamoto, T., Morimoto, Y., Ozawa, H., et al. (2022) · Neurocase · doi:10.1080/13554794.2022.2114838 · Cited by 7
Wang, G., Huang, H., Wang, Y., Yang, Y., Li, C., Luo, S., & Li, Y. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110897 · Cited by 6
Meyer, A., Truman, K. A., Totlani, J., William, C., Brown, H., Shah, S. R., Hirsch, D., Salem, M., Chang, T., Abdelsalam, R., et al. (2024) · The International Journal of Psychiatry in Medicine · doi:10.1177/00912174241310091 · Cited by 5
RetractedVelligan, D. I., Salinas, G. D., Belcher, E. D., Franzenburg, K. R., Suett, M., Thompson, S., & Hansen, R. T. (2025) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaf001 · Cited by 8
Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications
Stroup, T. S., Bareis, N., Rosenheck, R. A., Swartz, M. S., & McEvoy, J. P. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12109 · Cited by 5
Yun, J., Lee, J. S., Kang, S. H., Nam, B., Lee, S. J., Lee, S., Choi, J., Kim, C., & Chung, Y. (2019) · Korean Journal of Schizophrenia Research · doi:10.16946/kjsr.2019.22.2.21 · Cited by 6
Long-acting injectable HIV therapies: the next frontier: Republication
Thornhill, J. P., & Orkin, C. M. (2021) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000670 · Cited by 6
Brasso, C., Beoni, A. M., Colli, G., Mariani, G. N., & Rocca, P. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251367591 · Cited by 5
Cherniakov, I., Wagner, A. M., Eshet, R., Tiver, R., Bibi, D., Perlstein, I., Kalmanczhelyi, A., Sharon, N. A., Cohen, G., Ferderber, K., et al. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-025-01507-x · Cited by 4
Franzenburg, K. R., Hansen, R., Suett, M., Yaari, A., Levin, A. P., Sergerie, M., Kaplan, S., Sedigh, K., Heres, S., & Sajatovic, M. (2025) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaf032 · Cited by 5
Zhong, S., Wang, J., Guo, H., Zhou, J., & Wang, X. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.05.005 · Cited by 4
Schöttle, D., Wiedemann, K., Correll, C. U., Janetzky, W., Friede, M., Jahn, H., & Brieden, A. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.08.026 · Cited by 3
Self-citationCirnigliaro, G., Battini, V., Cafaro, R., Mosini, G., Vanzetto, S., Prodi, T., Macellaro, M., Leuzzi, R., Conti, D., Carnovale, C., et al. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2263650 · Cited by 4
A recovery-oriented day hospital in psychiatry: A springboard for reintegration
Dadi, G., Venet-Kelma, L., Mendy, M., Kern, L., Hauseux, P.-A., Masson, V. D., Raphaël Gaillard, B., Plaze, M., Morvan, Y., Moualla, M., et al. (2024) · L Encéphale · doi:10.1016/j.encep.2024.02.004 · Cited by 4
Netley, J., Gaul, J., & Ferguson, C. L. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001095 · Cited by 5
Yaegashi, H., Misawa, F., Noda, H., 藤井, 康., & Takeuchi, H. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.11.014 · Cited by 5
Nakajima, N., Mizoe, N., Misawa, F., Yamashita, T., So, R., Kitagawa, K., Tanimoto, K., Kishi, Y., 藤井, 康., & Takeuchi, H. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000347 · Cited by 4
Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia: Practical Considerations
Kverno, K. S., & Rozenberg, I. (2021) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20210611-04 · Cited by 6
Focus on neurodevelopmental conditions and antipsychotics prescription patterns
Serretti, A. (2024) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000555 · Cited by 4
Franzenburg, K. R., Hansen, R., Suett, M., Thompson, S. F., Sergerie, M., Garcia, D., & Margolese, H. C. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03274-9 · Cited by 4
Correll, C. U., Rohner, H., Dimalta, S., Göldner, R. S., Assion, H., Langner-Timm, S., Sande, C. N., Rodríguez–Jiménez, R., Bioque, M., Gahr, M., et al. (2026) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2026.2628198 · Cited by 4
Self-citationThe role of pharmaceutical formulation development in clinical trials of new medicinal products
Owczarek, B., & Markowicz-Piasecka, M. (2026) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2026.115101 · Cited by 3
The Role of Long-Acting Injectable Antipsychotics in the Early Treatment of Schizophrenia
Harrison, S. J., Antunes, J., Knight, K., Johnston, K., Mehawej, J., Sanchez, P., & Correll, C. U. (2026) · CNS Drugs · doi:10.1007/s40263-026-01294-9 · Cited by 3
Self-citationMartín‐Muñoz, J., Acuña, M. G., Carrión‐Mellado, N., Venzalá, M. B., Mantrana‐Ridruejo, L., Rico‐Villademoros, F., Rosado‐Tejero, L., & Caballero, E. U. (2022) · Early Intervention in Psychiatry · doi:10.1111/eip.13334 · Cited by 3
Citrome, L., Yagoda, S., Bidollari, I., & Wang, M. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.23m15095 · Cited by 5
Self-citationSancho-Echeverria, R., Aymerich, C., Rodríguez-Sánchez, J. M., Gil, P., Pedruzo, B., Torres, M. Á. G., Fusar‐Poli, P., Arango, C., & Catalán, A. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241243273 · Cited by 7
Comparing two transitioning strategies to paliperidone palmitate once-every-6-months
Correll, C. U., Johnston, K. L., Turkoz, I., Kutch, M., Knight, R. K., Doring, M., & Sajatovic, M. (2024) · CNS Spectrums · doi:10.1017/s1092852924000476 · Cited by 3
Self-citationSun, C. N., Temelie, A., Goulding, H., Clark, C., Yabs, M., & Fabian, T. J. (2024) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0072 · Cited by 3
Kim, E., Kim, S. C., Kim, S., Nam, B., Lee, K., Lee, B. J., Won, S., Lee, C. H., Jung, S.-W., Kim, S. I., et al. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.04.033 · Cited by 3
Self-citationSuetani, S., Kisely, S. R., Parker, S., Waterreus, A. J., Morgan, V. A., & Siskind, D. J. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211036032 · Cited by 3
Pippal, N., Halder, S., Srivastava, S., Kar, R., Gupta, R., & Almeida, E. A. (2021) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2021.1994613 · Cited by 3
Marić, N. P., Petrović, S. A., Russo, M., Jerotić, S., Ristić, I., Savić, B., Pemovska, T., Milutinović, M., Ribić, E., Markovska-Simoska, S., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.796719 · Cited by 4
Waters, H. C., Stellhorn, R., Touya, M., Fitzgerald, H. M., Bhattacharjee, S., & Citrome, L. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2178770 · Cited by 4
Self-citationUtilization of psychotropic medicines in Romania during 1998–2018
Iaru, I., Bucșa, C., Farcaş, A., Pop, C., Cristina, A., Armean, S., Brumboiu, I., Voștinaru, O., & Mogoșan, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1157231 · Cited by 5
Capuzzi, E., Forti, C. L. D., Caldiroli, A., Cova, F., Surace, T., Buoli, M., & Clerici, M. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000516 · Cited by 5
Catatonia-related adverse outcomes after long-acting injectable antipsychotics: Case series
Dragonetti, J. D., Posada, J. G., Key, R. G., & Kugler, J. (2024) · SAGE Open Medical Case Reports · doi:10.1177/2050313x241229008 · Cited by 3
Jasuja, G. K., Reisman, J. I., Miller, D. R., Ansara, E. D., Chiulli, D. L., Moore, T. D., Ourth, H. L., Tran, M. H., Smith, E. G., Morreale, A. P., et al. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae007 · Cited by 3
Zaniolo, O., Ghetti, G., Povero, M., & Pradelli, L. (2019) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v20i1.1393 · Cited by 3
Extended lifetime expectancy in schizophrenia, role of measurement based care
Helldin, L., Mohn, C., Olsson‐Tall, M., Härd, I. V. D., & Olsson, A.-K. (2024) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2024.10.012 · Cited by 5
Kang, N., Jo, A., Joo, S. W., Lee, J. S., Lee, K. Y., Kim, Y. S., Jeong, J. H., Lee, J., Lee, J., & Kim, S. H. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251333987 · Cited by 2
de Filippis, R., D’Onofrio, E., Liparota, G., Scaramuzzino, A., Aguglia, A., Amerio, A., Serafini, G., & Fazio, P. D. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2551636 · Cited by 4
Tunagur, E. M. K., & Tunagür, M. T. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-07801-y · Cited by 3
Liu, Z., Chen, W., Wang, X. Q., Huang, J., Gou, M., Han, H., Wang, J. P., Wang, D.-H., Chen, S., Xie, T., et al. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbag009 · Cited by 3
Performance in Practice: Practice Assessment Tool for the Care of Patients With Schizophrenia
Fochtmann, L. J., Medicus, J., & Hong, S.-H. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20200034 · Cited by 3
Molteni, L., Piccoli, E., Grancini, B. M., Gobbo, D., & Dell’Osso, B. M. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.09.353 · Cited by 2
Stump, T. A., Nelson, L. A., Liu, Y., Kriz, C. R., Iuppa, C. A., Diefenderfer, L. A., Lang, S. E., Elliott, E. S. R., & Sommi, R. W. (2021) · Mental Health Clinician · doi:10.9740/mhc.2021.01.012 · Cited by 2
Guiguet‐Auclair, C., Bernard, L., Boisgard, S., Cardinaud, Z., Fernandes, J., Debost‐Legrand, A., Gregoire, E., Lanquetin, J.-P., Morin, N., Lopes, E., et al. (2023) · Journal of Advanced Nursing · doi:10.1111/jan.15709 · Cited by 2
Sánchez‐Gistau, V., Moreno, M. J., Gómez-Lus, S., Sicras‐Mainar, A., & Crespo‐Facorro, B. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1207307 · Cited by 2
Uribe, E. S., Mundo, S. E. O., Garza, R., Gonzalez-Colmenero, F. D., Sanchez, L. M., Cantu, C., Arellano, M., Montemayor, Y. Y. H., Morales, P., Juarez, S. M., et al. (2023) · Psychiatry Investigation · doi:10.30773/pi.2022.0216 · Cited by 1
Miranda, J. J. F., Díaz-Fernández, S., Piorno, F. J. C., & Lopez-Munoz, F. J. (2024) · Biomedicines · doi:10.3390/biomedicines12010165 · Cited by 4
Isayeva, U., Manchia, M., Collu, R., Primavera, D., Deriu, L., Caboni, E., Iaselli, M. N., Sundas, D., Tusconi, M., Pinna, F., et al. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.02.019 · Cited by 3
Nanoparticle-Based Drug Delivery for Infectious Diseases
Sultana, A., & Nayan, M. U. (2024) · Springer eBooks · doi:10.1007/978-981-97-3925-7_13 · Cited by 2
Fuente‐Moreno, M., Cahir, C., Passos, V. L., Bennett, K., Walsh, C. A., Hermida‐González, P., de Loño, J. P., Abella, M., Baladón, L., Rubio-Valera, M., et al. (2025) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16399 · Cited by 4
Roach, M., Lin, D., Graf, M., Pednekar, P. P., Chou, J. W., Benson, C. J., & Doshi, J. A. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.10-aa.s2 · Cited by 3
Abdel‐Baki, A., Poulin, É., Medrano, S., Padilha, P. P. D. O., Stip, É., & Potvin, S. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2079531 · Cited by 2
Miranda, J. J. F., Díaz-Fernández, S., & Lopez-Munoz, F. J. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210701160013 · Cited by 2
Lemons, A., Iuppa, C. A., Kriz, C. R., Diefenderfer, L. A., Nelson, L. A., Lang, S. E., Elliott, E. S. R., Moon, J., & Sommi, R. W. (2022) · Mental Health Clinician · doi:10.9740/mhc.2022.06.175 · Cited by 2
Prescribing patterns of long-acting injectable antipsychotics in a community setting in South Africa
Veyej, N., & Moosa, M. Y. H. (2022) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v28i0.1809 · Cited by 4
Paliperidone palmitate intramuscular 6-monthly formulation in schizophrenia: a profile of its use
Blair, H. A. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00931-9 · Cited by 2
Schöttle, D., Janetzky, W., Therrien, F., & Wiedemann, K. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04651-w · Cited by 2
Depot preparation in schizophrenia: Indian outlook
Shah, M. S., Parikh, D., & Karia, S. (2018) · Annals of Indian Psychiatry · doi:10.4103/aip.aip_41_18 · Cited by 2
The Long-Acting Injectable Antipsychotics in Clinical Practice
Lee, K. Y. (2019) · 신경정신의학 · doi:10.4306/jknpa.2019.58.1.29 · Cited by 2
Antipsychotic Polypharmacy and High Doses in a Rural Portuguese Community Mental Health Service
Ramos, S. F., Cruz, D., Jesús, B., Correia, J., Vaz, I. F., & Mendes, J. C. (2021) · Revista Portuguesa de Psiquiatria e Saúde Mental · doi:10.51338/rppsm.2021.v7.i3.163 · Cited by 2
Janzen, D., Bolton, J. M., Leong, C., Kuo, I. F., & Alessi‐Severini, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.879224 · Cited by 4
Miranda, J. J. F., & Díaz-Fernández, S. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s425516 · Cited by 2
Chang, B.-C., Kuo, M., Lee, C., Chu, Y.-L., Chen, K., Tung, C.-L., Yang, Y., Hung, C.-S., Tsai, J., & Chuang, H. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s484717 · Cited by 1
Clinical Applications of Long Acting Injectables: Systemic and Local Drug Delivery
Witika, B. A., Poka, M., Makoni, P. A., Ramazani, F., & Nkanga, C. I. (2025) · Springer eBooks · doi:10.1007/978-3-031-72302-5_7 · Cited by 2
Schulze, A.-T., Schurr, T., Post, F., Frajo-Apor, B., Díaz‐Caneja, C. M., Fleischhacker, W. W., Davidson, M. L., & Hofer, A. (2025) · European Psychiatry · doi:10.1192/j.eurpsy.2025.10086 · Cited by 1
Perlstein, I., Meyer, J. M., Yue, Z., Ivaturi, V. D., Franzenburg, K. R., Suett, M., Hansen, R., Wagner, A. M., Phatak, A., & Singh, R. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03329-x · Cited by 1
Weiden, P. J., Strand, L. N., Doane, M. J., Arevalo, C., McGrory, J. A., Achtyes, E. D., Harvey, P. D., Kane, J. M., Saklad, S. R., Trotter, J. P., et al. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s528018 · Cited by 2
Self-citationGiorgio, A. D., Massaro, A., Bergamelli, E., Libri, C., Bondi, E., & Canali, M. E. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.09.014 · Cited by 1
Tunagur, E. M. K., & Tunagür, M. T. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120989 · Cited by 1
Wu, K.-F., Yang, Y.-H., Hung, C.-S., Tsai, J., & Chuang, H. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261419626 · Cited by 1
Voegel, A., Naranjo, R. R., Díaz, L., Eynde, C. V., Wang, Y., Pilon, D., Benson, C. J., & Citrome, L. (2026) · Patient Preference and Adherence · doi:10.2147/ppa.s570441 · Cited by 1
Self-citationThe duration of active psychosis and relationship with early psychosis outcomes
Crowley, P., Boland, F., Thompson, A., McGorry, P. D., O'Donoghue, B. N., & Lyne, J. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.03.014 · Cited by 1
Metadata
- Authors
- Correll, C. U., Citrome, L., Haddad, P. M., Lauriello, J., Olfson, M., Calloway, S. M., & Kane, J. M.
- Affiliations
- Hofstra University (US)
- New York Medical College (US)
- University of Manchester (GB)
- University of Missouri (US)
- Columbia University (US)
- Missouri Department of Social Services (US)
- Northwell Health (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2016-09-30
- Volume
- 77
- Issue
- Suppl 3
- Pages
- 1-24
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2527103551
- Cited by
- 372
- References
- 0
- Citations by year
- 2026: 28 · 2025: 36 · 2024: 37 · 2023: 54 · 2022: 40 · 2021: 50 · 2020: 36 · 2019: 49 · 2018: 22 · 2017: 20
- FWCI
- 27.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Social Sciences › Psychology › Clinical Psychology › Family Caregiving in Mental Illness
- Keywords
- long-acting injectable antipsychotics, schizophrenia, first-episode schizophrenia, medication adherence, relapse prevention, cost-effectiveness, adverse effects, weight gain, metabolic effects, extrapyramidal symptoms, prolactin elevation, stakeholder perspectives, clinical guidelines
- MeSH terms
- Chronic Disease, Cost-Benefit Analysis, Delayed-Action Preparations, Humans, Injections, Intramuscular, Mental Health Services, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Utilization Review, Randomized Controlled Trials as Topic, Treatment Outcome, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.